Trial · NCT01180036
MEmbranous Nephropathy Trial Of Rituximab
NCT01180036, Phase 2, Phase 3, Completed, Mayo Clinic; results first posted 2019-04-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MEmbranous Nephropathy Trial Of Rituximab. Trials, record NCT01180036. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01180036
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MEmbranous Nephropathy Trial Of Rituximab
- NCT number
- NCT01180036
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 130 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Rituximab, Cyclosporine
- First posted
- 2010-08-11
- Last updated
- 2019-04-30
- Results first posted
- 2019-04-30
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Remission Status | 24 months after randomization | The number of subjects to reach the composite of maintaining complete remission or partial remission at 24 months after randomization will be the primary endpoint. |
| Secondary | Remission Status | 12 months after randomization | The number of subjects to reach either complete remission or partial remission at 12 months after randomization. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Remission Status | 24 months after randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Remission Status | 12 months after randomization | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Remission Status | Rituximab Treatment Arm | 39 | Participants | ||
| Remission Status | Cyclosporine Treatment Arm | 13 | Participants | ||
| Remission Status | Rituximab Treatment Arm | 39 | Participants | ||
| Remission Status | Cyclosporine Treatment Arm | 34 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab Treatment Arm | 65 | |
| Overall Study | STARTED | Cyclosporine Treatment Arm | 65 | |
| Overall Study | COMPLETED | Rituximab Treatment Arm | 65 | |
| Overall Study | COMPLETED | Cyclosporine Treatment Arm | 65 | |
| Overall Study | NOT COMPLETED | Rituximab Treatment Arm | 0 | |
| Overall Study | NOT COMPLETED | Cyclosporine Treatment Arm | 0 |
Source ClinicalTrials.gov
Adverse events58
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Benign neoplasms | General disorders | Rituximab Treatment Arm | 1 | 65 | 1 |
| other | Benign neoplasms | General disorders | Cyclosporine Treatment Arm | 1 | 65 | 1 |
| other | Blood and lymphatic system | Blood and lymphatic system disorders | Rituximab Treatment Arm | 1 | 65 | 1 |
| other | Blood and lymphatic system | Blood and lymphatic system disorders | Cyclosporine Treatment Arm | 3 | 65 | 3 |
| other | Cardiovascular | Cardiac disorders | Rituximab Treatment Arm | 5 | 65 | 6 |
| other | Cardiovascular | Cardiac disorders | Cyclosporine Treatment Arm | 11 | 65 | 14 |
| other | Ear | Ear and labyrinth disorders | Rituximab Treatment Arm | 3 | 65 | 3 |
| other | Ear | Ear and labyrinth disorders | Cyclosporine Treatment Arm | 1 | 65 | 2 |
| other | Endocrine or metabolic | Endocrine disorders | Rituximab Treatment Arm | 7 | 65 | 9 |
| other | Endocrine or metabolic | Endocrine disorders | Cyclosporine Treatment Arm | 6 | 65 | 15 |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab Treatment Arm | 0 | 65 |
| Total, all-cause mortality | Cyclosporine Treatment Arm | 0 | 65 |
| Total, other adverse events | Rituximab Treatment Arm | 46 | 65 |
| Total, other adverse events | Cyclosporine Treatment Arm | 51 | 65 |
| Total, serious adverse events | Rituximab Treatment Arm | 11 | 65 |
| Total, serious adverse events | Cyclosporine Treatment Arm | 20 | 65 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Rituximab Treatment Arm vs Cyclosporine Treatment Arm: Remission Status | Trial comparisons |
| Rituximab Treatment Arm vs Cyclosporine Treatment Arm: Remission Status | Trial comparisons |
| Rituximab Treatment Arm vs Cyclosporine Treatment Arm: deaths from any cause | Trial comparisons |
| Rituximab Treatment Arm vs Cyclosporine Treatment Arm: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01180036
GET https://conductscience.org/api/trials/v1/NCT01180036/events?page=2